BioTime, Inc. (OTCBB: BTIM), is engaged in the research and development of aqueous-based synthetic solutions that may be used as plasma expanders, organ preservation solutions, or solutions to replace blood volume during low temperature surgery. These products are intended for several important medical applications including:
the treatment of hypovolemia caused by surgical blood loss
the emergency treatment of blood loss due to traumatic injury
the replacement of all of a patient’s circulating blood during cardiac surgery and neurosurgery that involve lowering the patient’s body temperature to hypothermic levels
the preservation of body organs and tissues awaiting transplant


Judith Segall (VP Operations)

Jeffrey Nickel (VP Business Development & Marketing)

Steven Seinberg (CFO/Treasurer)

Harold Waitz (VP Engineering & Regulatory Affairs)

Hal Sternberg (VP Research)

View more details about all 7 people at Biotime